Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of D311 and D107 Compared to CKD-339 in Healthy Adult Volunteers
NCT07748702Phase 1Not yet recruiting
- Sponsor
- Chong Kun Dang Holdings
- Start
- Aug 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan + levamlodipine + chlorthalidone in hypertension (HTN) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration at 72 hours and Maximum Observed Plasma Concentration at 72 hours. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
telmisartan + levamlodipine + chlorthalidone
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07748702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07748702.